Cargando…

Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology

BACKGROUND: Microarrays have revolutionized breast cancer (BC) research by enabling studies of gene expression on a transcriptome-wide scale. Recently, RNA-Sequencing (RNA-Seq) has emerged as an alternative for precise readouts of the transcriptome. To date, no study has compared the ability of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fumagalli, Debora, Blanchet-Cohen, Alexis, Brown, David, Desmedt, Christine, Gacquer, David, Michiels, Stefan, Rothé, Françoise, Majjaj, Samira, Salgado, Roberto, Larsimont, Denis, Ignatiadis, Michail, Maetens, Marion, Piccart, Martine, Detours, Vincent, Sotiriou, Christos, Haibe-Kains, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289354/ https://www.ncbi.nlm.nih.gov/pubmed/25412710 http://dx.doi.org/10.1186/1471-2164-15-1008

Ejemplares similares

No significant viral transcription detected in whole breast cancer transcriptomes
por: Fimereli, Danai, et al.
Publicado: (2015)

Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays
por: Jose, Vinu, et al.
Publicado: (2018)

Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer
por: Rothé, Françoise, et al.
Publicado: (2011)

Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis
por: Azim, Hatem A., et al.
Publicado: (2013)

Correction: Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis
por: Azim, Hatem A., et al.
Publicado: (2013)

A fuzzy gene expression-based computational approach improves breast cancer prognostication
por: Haibe-Kains, Benjamin, et al.
Publicado: (2010)

Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome
por: Fumagalli, Debora, et al.
Publicado: (2015)

Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome
por: Venet, David, et al.
Publicado: (2020)

Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer Patients
por: Rothé, Françoise, et al.
Publicado: (2021)

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
por: Wirapati, Pratyaksha, et al.
Publicado: (2008)

A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all?
por: Haibe-Kains, B., et al.
Publicado: (2008)

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial
por: Sonnenblick, Amir, et al.
Publicado: (2015)

DNA methylation profiling reveals a predominant immune component in breast cancers
por: Dedeurwaerder, Sarah, et al.
Publicado: (2011)

Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations
por: Nguyen, Bastien, et al.
Publicado: (2018)

Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues
por: Toussaint, Jérôme, et al.
Publicado: (2009)

Uncovering the genomic heterogeneity of multifocal breast cancer
por: Desmedt, Christine, et al.
Publicado: (2015)

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer
por: Sonnenblick, Amir, et al.
Publicado: (2015)

Comparison of prognostic gene expression signatures for breast cancer
por: Haibe-Kains, Benjamin, et al.
Publicado: (2008)

Multiple-input multiple-output causal strategies for gene selection
por: Bontempi, Gianluca, et al.
Publicado: (2011)

nuID: a universal naming scheme of oligonucleotides for Illumina, Affymetrix, and other microarrays
por: Du, Pan, et al.
Publicado: (2007)

The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1–98 trial
por: Desmedt, Christine, et al.
Publicado: (2009)

HER2-Positive Circulating Tumor Cells in Breast Cancer
por: Ignatiadis, Michail, et al.
Publicado: (2011)

Relative impact of key sources of systematic noise in Affymetrix and Illumina gene-expression microarray experiments
por: Kitchen, Robert R, et al.
Publicado: (2011)

Timing evolution of lobular breast cancer through phylogenetic analysis
por: Fimereli, Danai, et al.
Publicado: (2022)

The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group
por: Maetens, Marion, et al.
Publicado: (2017)

Low CD10 mRNA Expression Identifies High-Risk Ductal Carcinoma In Situ (DCIS)
por: Toussaint, Jérôme, et al.
Publicado: (2010)

Experimental comparison and cross-validation of the Affymetrix and Illumina gene expression analysis platforms
por: Barnes, Michael, et al.
Publicado: (2005)

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
por: Bareche, Y, et al.
Publicado: (2018)

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer
por: Ignatiadis, Michail, et al.
Publicado: (2016)

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
por: Raspé, Eric, et al.
Publicado: (2017)

Direct integration of intensity-level data from Affymetrix and Illumina microarrays improves statistical power for robust reanalysis
por: Turnbull, Arran K, et al.
Publicado: (2012)

Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients
por: Haibe-Kains, B., et al.
Publicado: (2013)

Inter- and intra-reproducibility of genotypes from sheep technical replicates on Illumina and Affymetrix platforms
por: Berry, Donagh P., et al.
Publicado: (2016)

Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer
por: Loi, Sherene, et al.
Publicado: (2009)

Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer
por: Nguyen, Bastien, et al.
Publicado: (2019)

Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach
por: Bareche, Yacine, et al.
Publicado: (2019)

Sources of variation in Affymetrix microarray experiments
por: Zakharkin, Stanislav O, et al.
Publicado: (2005)

Equalizer reduces SNP bias in Affymetrix microarrays
por: Quigley, David
Publicado: (2015)

Combining Affymetrix microarray results
por: Stevens, John R, et al.
Publicado: (2005)

Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial
por: De Caluwé, Alex, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h8i32ekau7np7meqr059797p4t